Larimar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Larimar Therapeutics

11/08/2022 23:01

* Larimar Therapeutics Inc  LRMR.OQ  reported a quarterly
adjusted
loss of 47 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 57 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Larimar Therapeutics Inc's reported EPS for the quarter
was a
loss of 47 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Larimar Therapeutics Inc shares had held steady so far
this
quarter and lost 81.8% so far this year.
    * The company reported a quarterly loss of $8.67 million.
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $5.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 10:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.57          -0.47          Beat
 Mar. 31 2022      -0.51          -0.49          Beat
 Dec. 31 2021      -0.72          -0.50          Beat
 Sep. 30 2021      -0.64          -0.92          Missed